News &
Publications

Presentation
October 24, 2025
Preliminary safety, pharmacokinetics, and antitumor activity of HLD-0915, a first-in-class oral RIPTAC binding androgen receptor (AR) and bromodomain 4 (BRD4), in patients with metastatic castrate resistant prostate cancer (mCRPC)

Oral presentation in a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on the first human data for HLD-0915, our first-in-class oral RIPTAC™ therapeutic, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Poster
June 2, 2025
An Oral Prostate Cancer RIPTAC Therapeutic in Phase 1 for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting for clinical trial in progress for orally administered HLD-0915 in Phase 1/2 study in patients with mCRPC

Poster
April 30, 2025
An orally bioavailable RIPTAC therapeutic for p53^Y220C mutant tumors

Poster presentation at American Association for Cancer Research (AACR) annual meeting of RIPTAC therapeutics for p53^Y220C mutant tumors.

Publication
August 7, 2024
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Heterobifunctional Small Molecule Strategy for Cancer Selective Therapies

Halda has applied a chemical biology model to demonstrate proof-of-mechanism and pharmacology of the RIPTAC therapeutic modality for the precision treatment of cancer. These studies show selective cell killing enabled by RIPTACs via a novel hold and kill mechanism that does not require the target protein to be an oncogene driver and, therefore, has the potential to overcome bypass mechanisms of drug resistance, a common limitation of today’s precision oncology medicines. As a platform approach, several different pan-essential cellular proteins were incorporated into RIPTACs and shown to be successful in forming ternary complexes between the target protein, the RIPTAC molecule, and a pan-essential protein, resulting in cancer selective cell death.

Poster
April 17, 2023
Prostate Cancer RIPTAC^TM Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-Resistant Prostate Cancer

Poster presentation at American Association for Cancer Research (AACR) annual meeting demonstrates oral efficacy of RIPTAC therapeutics as a monotherapy for the treatment of prostate cancer.

Poster
February 16, 2023
An Oral RIPTAC^TM Therapeutic for Prostate Cancer

Poster presentation at American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium features preclinical data for a RIPTAC therapeutic candidate for the treatment of prostate cancer, demonstrating superior in vivo efficacy to standard of care agent in prostate cancer, enzalutamide.

Publication
January 2, 2023
Regulated Induced Proximity Targeting Chimeras (RIPTACs™): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively

Halda has published a chemical biology demonstration of the RIPTAC therapeutic concept as a novel heterobifunctional drug modality to selectively treat cancers. The study establishes our novel approach with evidence of a hold and kill mechanism where a RIPTAC therapeutic kills cancer cells selectively by facilitating the formation of a neo protein-protein interaction interface between a tumor-specific protein and a pan-essential protein. Several chemical biology approaches were explored to exemplify mechanistic principles that are currently being applied to develop future RIPTAC therapeutics.

February 28, 2025
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
Nature Reviews Drug Discovery

November 10, 2023
10 Startups to Watch
C&E News

March 13, 2023
Proximity-inducing drugs get closer
Nature Reviews Drug Discovery

February 14, 2023
‘Rip’ it up and start again: Halda Therapeutics unveils Riptac platform, $76M investment
BioWorld

February 14, 2023
Halda emerges from stealth with bifunctional molecules to treat cancer
C&E News

June 23, 2021
Biotech Start-Up Halda Therapeutics Opens SciPark HQ
New Haven Independent